top of page

Calli Dendrou PhD Sir Henry Dale Fellow PI

Calli received her B.Sc. from Imperial College London in 2005 (Forbes Memorial Medal Winner for Excellence in Biology), focusing on Immunology and Genetics. To further develop her interdisciplinary interest she joined the Diabetes and Inflammation Laboratory (Cambridge Institute for Medical Research) to obtain a Ph.D. under the supervision of Profs Linda Wicker and John Todd, having been awarded a Wellcome Trust studentship in Infection and Immunity. This work culminated in a seminal study showing that the immunological consequences of genome-wide association data can be dissected to inform our understanding of disease mechanisms.


After completing her degree in 2009 she joined the laboratory of Prof Lars Fugger as a postdoctoral researcher to investigate how the data explosion arising from advances in genomics can be converted into clinically relevant information - in particular through comparative analyses across different diseases. To date this has led to the first study demonstrating that elucidating the functional impact of disease-associated genetic variation can have important implications for predicting clinical outcome. Calli has also won the Thomas Willis Early Career Researcher Prize in 2013 and the Oxford Multiple Sclerosis Young Investigator Award in 2014. 

In 2017 Calli moved to the Henry Wellcome Building of Genomic Medicine to begin her career as a PI. The key research interests of her group are to better understand the architecture of genetic predisposition across different autoimmune and immune-mediated diseases, and to explore the functional relevance and potential clinical utility of such cross-comparisons.


BSc: 2002-2005, Biology, Imperial College London, UK


PhD: 2005-2009, Four-Year Wellcome Trust Studentship in Infection and Immunity (Thesis title: Gene-to-phenotype studies for type 1 diabetes),

Prof Linda S. Wicker & Prof John A. Todd FRS, FMedSci. Newnham College, University of Cambridge, UK


Postdoctoral Fellow: 2010-2013, Nuffield Department of Clinical Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, UK


Senior Postdoctoral Fellow: 2013-2016, Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of Oxford, UK





Dendrou CA, McVean G, Fugger L. Neuroinflammation - using big data to inform clinical practice (2016) Nature Reviews Neurology

Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, Compston A, Johnson AR, Everett C, Bell JI, Karpe F, Ultsch M, Eigenbrot C, McVean G, Fugger L.  Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity (2016)  Science Translational Medicine

Dendrou C.A., Fugger L, Friese M.A., (2015) Immunopathology of multiple sclerosis. Nature Reviews Immunology

Dendrou C.A., Bell J.I. & Fugger L. (2013) Bedside to Bench. Weighing in on autoimmune disease: Big data tip the scale. Nature Medicine, 19, 138-139. (2 citations)

Gregory A.P.*, Dendrou C.A.*, Attfield K.E., et al. (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature, 23, 508-511. (63 citations)

*Joint first authors.

Recommended by the Faculty of 1000.


Dendrou C.A., Plagnol V., Fung E. et al. (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable bioresource. Nature Genetics, 41, 1011-1015.  (116 citations)

Recommended by the Faculty of 1000.


Dendrou C.A., Fung E., Esposito L., Todd J.A., Wicker L.S. & Plagnol V. (2009) Fluorescence intensity normalisation: correcting for time effects in large-scale flow cytometric analysis. Advances in Bioinformatics, e476106. (2 citations)


Dendrou C.A. & Wicker L.S. (2008) The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. Journal of Clinical Immunology, 28, 685-696. (22 citations)





Dendrou C.A., Bell J.I. & Fugger L. (2013) A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis. Pharmacogenomics, 14, 1397-1404.




Kaur GGras SMobbs JIVivian JPCortes ABarber TKuttikkatte SBJensen LTAttfield KEDendrou CACarrington MMcVean GPurcell AWRossjohn JFugger L. Structural and regulatory diversity shape HLA-C protein expression levels. (2017) Nature Communications

Friese, M. A., Schattling, B. and Fugger, L. (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis,  Nature Reviews Neurology


Pekalski M.L., Ferreira R.C., Coulson R.M., Cutler A.J., Guo H., Smyth D., Downes K., Dendrou C.A. et al. (2013) Post-thymic expansion in human CD4 naive T cells defined by expression of functional high affinity IL-2 receptors. The Journal of Immunology, 190, 2554-2566. (3 citations).


Attfield K.E., Dendrou C.A. & Fugger L. (2012) Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis. Immunological Reviews, 248, 10-22. (4 citations)


Fraser H.I., Dendrou C.A., Healy B. et al. (2010) Nonobese diabetic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene. The Journal of Immunology, 184, 5075-5084.  (15 citations)

Rated in top 10% of articles published in the journal in 2010.


Morriswood B., Ryzhakov G., Puri C., Arden S. D., Roberts R. C., Dendrou C., et al. (2007) T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signaling and cell adhesion. Journal of Cell Science, 120, 2574-2585. (26 citations)

bottom of page